Top Abstract Purchase Related
Home
>
Node
>
Subnode

Significance of FCM-DNA measurement in detecting minimal residual disease in leukemia

Zhang, R.X.; Yao, E.G.

Chinese Medical Journal 103(10): 826-830

1990

ISSN/ISBN: 0366-6999
PMID: 2125256
Document Number: 366044
Using flow cytometry (FCM), we measured the DNA content of bone marrow from 25 patients with acute leukemia (AL) in complete remission (CR) and followed them up for 0.5 to 1 year. Five of 13 patients in early relapse had normal DNA index (DI), while the remaining 8 showed DNA aneuploidy 1.5 to 5 months (mean 2.6 months) before relapse. The relapse rate was higher in CR patients with DNA aneuploidy (88.9%) than in those with normal DI (31.3%, P less than 0.05). Intensive chemotherapy was helpful to prolong CR duration in CR patients with DNA aneuploidy. DNA measurement by FCM was considered a reliable method for detecting minimal residual disease (MRD), and the appearance of DNA aneuploidy might predict a relapse of CR.

Document emailed within 1 workday
Secure & encrypted payments

Tang, Y.; Deng, C.; Du, Q.; Li, G.; Zeng, Z.; Zhang, J.; Miu, S. 2001: Hypermethylation of the calcitonin gene as molecular genetic marker in detecting minimal residual disease of leukemia Zhonghua Nei Ke Za Zhi 40(4): 226-228
Walle, A.J.; Niedermayer, W. 1985: Aneuploidy as a marker of minimal residual disease in leukemia Cancer Detection and Prevention 8(1-2): 303-315
Hagenbeek, A. 1992: Minimal residual disease in leukemia: state of the art 1991 Leukemia 6(Suppl 2): 12-16
Mód, A.; Tamáska, J.; Adám, E.; Gidáll, J.; Poros, A.; Király, A.; Natonek, K.; Pálóczi, K.; Hollán, Z. 1991: Importance of the detection of minimal residual disease in the management of acute leukemia Orvosi Hetilap 132(24): 1291-1296; 1299
Thörn, I.; Olsson-Strömberg, U.; Ohlsen, C.; Jonsson, A-Maria.; Klangby, U.; Simonsson, B.; Barbany, G. 2005: The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia Haematologica 90(11): 1471-1476
Zuna, J.; Hrusák, O.; Kalinová, M.; Muzíková, K.; Zörnerová, T.; Starý, J.; Trka, J. 2000: Monitoring minimal residual disease in pediatric patients with acute lymphoblastic leukemia Vnitrni Lekarstvi 46(8): 465-469
Szczepański, T.; Sońta-Jakimczyk, D.; Van Dongen, J.J. 2003: Minimal residual disease in childhood acute lymphoblastic leukemia: diagnosis of the 21 century Przeglad lekarski 60 Suppl. 5: 1-4
Dĕdic, K.; Zák, P. 2003: Immunohistochemical detection and quantification of minimal residual disease using DBA.44 antibodies in trephination biopsies of hairy cell leukemia Ceskoslovenska Patologie 39(4): 175-177
Cathomas, G.; McGandy, C.; Diamantis, I.; Tichelli, A.; Gudat, F. 1994: Detection of bcr-abl transcripts in "minimal residual disease" in chronic myelogenous leukemia by nested polymerase chain reaction (PCR) Verhandlungen der Deutschen Gesellschaft für Pathologie 78: 314-317
Mlcáková, A.; Babusíková, O. 2003: Multiparametric flow cytometry in detection of minimal residual disease in acute lymphoblastic leukemia of early B-cell phenotype Neoplasma 50(6): 416-421
Kisilichina, D.G.; Lugovskaia, C.A.; Naumova, E.V.; Pochtar', M.E.; Nikitin, E.A.; Dolgov, V.V. 2014: The prognostic value of evaluation of minimal residual disease using technique of flow cytofluorometry during application of therapy of chronic lymphatic leukemia Klinicheskaia Laboratornaia Diagnostika 59(11): 26-30
Bilhou-Nabéra, C.; Marit, G.; Gharbi, M.J.; Salzes, S.; Mahon, F.X.; Broustet, A.; Reiffers, J.; Bernard, P. 1995: Chronic myelocytic leukemia patients achieving complete cytogenetic conversion under interferon alpha therapy: minimal residual disease follow-up Leukemia 9(12): 2067-2070
Muñoz, L.; López, O.; Martino, R.; Brunet, S.; Bellido, M.; Rubiol, E.; Sierra, J.; Nomdedéu, J.F. 2000: Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia Haematologica 85(7): 704-710
Savva, N.N.; Belevtsev, M.V.; Savitskiĭ, V.P.; Migal', N.V.; Movchan, L.V.; Aleĭnikova, O.V. 2009: Role of three-color flow cytofluorometry in the algorithm for detection of minimal residual disease in children with acute lymphoblastic and acute myeloblastic leukemia Klinicheskaia Laboratornaia Diagnostika 12: 15-18
Maeda, Y.; Horiuchi, F.; Morita, S.; Matsuda, M.; Shirakawa, C.; Masaki, H.; Koyama, A.; Hamazaki, H.; Fujimoto, T.; Irimajiri, K. 1994: Detection of minimal residual disease using clonospecific primers for CDRIIi in patients with acute B lymphocytic leukemia with or without Philadelphia chromosome: possibility of clinical application as a tool for improving prognosis Experimental Hematology 22(9): 881-887
Takatsuki, H.; Umemura, T.; Sadamura, S.; Yamashita, S.; Goto, T.; Abe, Y.; Yufu, Y.; Inaba, S.; Nishimura, J.; Nawata, H. 1995: Detection of minimal residual disease by reverse transcriptase polymerase chain reaction for the PML/RAR alpha fusion mRNA: a study in patients with acute promyelocytic leukemia following peripheral stem cell transplantation Leukemia 9(5): 889-892
Cajozzo, A. 1990: Minimal residual disease in hematological neoplasms Recenti Progressi in Medicina 81(10): 655-657
San-Miguel, J.F.; Bartram, C.; Campana, D.; Andreeff, M. 1994: Minimal residual disease in hematologic malignancies Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion Suppl: 147-152
Matsuda, K. 2014: Evaluation of minimal residual disease using allele (mutation) -specific PCR Rinsho Byori. Japanese Journal of Clinical Pathology 62(6): 552-559
Yeoh, A.E.; Quah, T.C.; Jeyaseelan, K.; Lee, B.W.; Poh, K.S.; Sun, L. 1997: An evaluation of minimal residual disease in childhood acute lymphoblastic leukaemia Annals of the Academy of Medicine Singapore 26(3): 365-371